Shaad E. Abdullah

2.5k total citations
63 papers, 911 citations indexed

About

Shaad E. Abdullah is a scholar working on Oncology, Ophthalmology and Immunology. According to data from OpenAlex, Shaad E. Abdullah has authored 63 papers receiving a total of 911 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 24 papers in Ophthalmology and 24 papers in Immunology. Recurrent topics in Shaad E. Abdullah's work include Cancer Immunotherapy and Biomarkers (26 papers), Ocular Oncology and Treatments (24 papers) and Immunotherapy and Immune Responses (21 papers). Shaad E. Abdullah is often cited by papers focused on Cancer Immunotherapy and Biomarkers (26 papers), Ocular Oncology and Treatments (24 papers) and Immunotherapy and Immune Responses (21 papers). Shaad E. Abdullah collaborates with scholars based in United States, United Kingdom and Canada. Shaad E. Abdullah's co-authors include Román Pérez-Soler, Neil H. Segal, Brandon W. Higgs, Phillip A. Dennis, J. Carl Barrett, Song Wu, Matthew D. Hellmann, Michiel S. van der Heijden, Chen Gao and Todd Hembrough and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Shaad E. Abdullah

60 papers receiving 895 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shaad E. Abdullah United States	16	573	271	215	211	168	63	911
Sara M. Federico United States	17	346 0.6×	185 0.7×	177 0.8×	127 0.6×	324 1.9×	63	967
Francesco De Rosa Italy	18	694 1.2×	168 0.6×	102 0.5×	392 1.9×	291 1.7×	58	1.1k
Elizabeth Fabre France	22	725 1.3×	583 2.2×	367 1.7×	305 1.4×	441 2.6×	91	1.5k
Parisa Momtaz United States	14	1.5k 2.6×	362 1.3×	95 0.4×	499 2.4×	353 2.1×	40	1.8k
Ernest Marshall United Kingdom	17	482 0.8×	232 0.9×	82 0.4×	209 1.0×	287 1.7×	42	938
Suthee Rapisuwon United States	11	683 1.2×	158 0.6×	104 0.5×	246 1.2×	329 2.0×	30	997
Ashton A. Connor United States	14	520 0.9×	94 0.3×	219 1.0×	46 0.2×	250 1.5×	50	859
Lorenza Di Guardo Italy	15	987 1.7×	248 0.9×	49 0.2×	398 1.9×	360 2.1×	48	1.2k
Pieter‐Jan van Dam Belgium	16	335 0.6×	209 0.8×	278 1.3×	89 0.4×	214 1.3×	37	684
Alexander H. R. Varey Australia	15	360 0.6×	79 0.3×	175 0.8×	65 0.3×	504 3.0×	44	862

Countries citing papers authored by Shaad E. Abdullah

Since Specialization

Citations

This map shows the geographic impact of Shaad E. Abdullah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shaad E. Abdullah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shaad E. Abdullah more than expected).

Fields of papers citing papers by Shaad E. Abdullah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shaad E. Abdullah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shaad E. Abdullah. The network helps show where Shaad E. Abdullah may publish in the future.

Co-authorship network of co-authors of Shaad E. Abdullah

This figure shows the co-authorship network connecting the top 25 collaborators of Shaad E. Abdullah. A scholar is included among the top collaborators of Shaad E. Abdullah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shaad E. Abdullah. Shaad E. Abdullah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hassel, Jessica C., Alexander Greenshields‐Watson, Alexander Enk, et al.. (2024). Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action. Journal of Investigative Dermatology. 145(3). 559–572.e9. 8 indexed citations

Sullivan, Ryan J., Laura Collins, Manuel Rodrigues, et al.. (2023). Abstract 1035: Early ctDNA reduction is associated with better overall survival in the Ph 3 trial of tebentafusp in previously untreated metastatic uveal melanoma. Cancer Research. 83(7_Supplement). 1035–1035. 1 indexed citations

Arkenau, H-T., et al.. (2022). 728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors. Annals of Oncology. 33. S875–S875. 16 indexed citations

Ertuğrul, Duygu Çelik & Shaad E. Abdullah. (2022). A Decision-Making Tool for Early Detection of Breast Cancer on Mammographic Images. Tehnicki vjesnik - Technical Gazette. 29(5). 5 indexed citations

Ikeguchi, Alexandra P., Joseph J. Sacco, Jason J. Luke, et al.. (2022). Analysis of the effect of systemic corticosteroids on survival from tebentafusp in a phase 3 trial of metastatic uveal melanoma.. Journal of Clinical Oncology. 40(16_suppl). 9584–9584. 1 indexed citations

Chmielowski, Bartosz, Ellen Kapiteijn, Paolo A. Ascierto, et al.. (2021). 1018P Characterization of liver function tests following tebentafusp in phase III randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma (mUM). Annals of Oncology. 32. S856–S857. 1 indexed citations

Salama, April K.S., Jens T. Siveke, Alfonso Berrocal, et al.. (2021). 1014P Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma. Annals of Oncology. 32. S855–S855. 3 indexed citations

Cruz‐Merino, Luis de la, Zeynep Eroglu, Linda Collins, et al.. (2021). 1770P Genomic correlates of clinical outcomes in patients with metastatic uveal melanoma (mUM) treated with tebentafusp (tebe). Annals of Oncology. 32. S1214–S1215. 2 indexed citations

Piulats, Josep M., Jason J. Luke, Linda Collins, et al.. (2021). 1013P Similar overall survival in tebentafusp-treated 2L+ metastatic uveal melanoma regardless of prior immunotherapy. Annals of Oncology. 32. S854–S854. 2 indexed citations

10.

Zhang, Qu, Jia Luo, Song Wu, et al.. (2020). Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discovery. 10(12). 1842–1853. 221 indexed citations

11.

Sacco, Joseph J., Richard D. Carvajal, Marcus O. Butler, et al.. (2020). 64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM). Annals of Oncology. 31. S1442–S1443. 24 indexed citations

12.

Segal, Neil H., Sai‐Hong Ignatius Ou, Ani Sarkis Balmanoukian, et al.. (2019). Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. European Journal of Cancer. 109. 154–161. 68 indexed citations

13.

Pegram, Mark D., Erika Hamilton, Antoinette R. Tan, et al.. (2018). Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer. Annals of Oncology. 29. iii8–iii8. 16 indexed citations

14.

O’Donnell, Peter H., Christophe Massard, Bhumsuk Keam, et al.. (2018). Abstract CT031: Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma. Cancer Research. 78(13_Supplement). CT031–CT031. 6 indexed citations

15.

Cho, Daniel C., Amit Mahipal, Afshin Dowlati, et al.. (2018). Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).. Journal of Clinical Oncology. 36(15_suppl). 8517–8517. 29 indexed citations

16.

Hollebecque, Antoine, Zev A. Wainberg, Jaffer A. Ajani, et al.. (2018). Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.. Journal of Clinical Oncology. 36(15_suppl). 4032–4032. 5 indexed citations

17.

Higgs, Brandon W., Chris Morehouse, Michael Kuziora, et al.. (2018). IFNγ mRNA signature (IFNγ sig), circulating tumor DNA (ctDNA), and survival in NSCLC or urothelial cancer (UC) treated with durvalumab (D).. Journal of Clinical Oncology. 36(5_suppl). 51–51.

18.

Abdullah, Shaad E. & Román Pérez-Soler. (2011). Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer. 118(14). 3455–3467. 71 indexed citations

19.

Abdullah, Shaad E., et al.. (2010). Screening for Lung Cancer with Low-Dose Computed Tomography: A Systematic Review and Meta-Analysis of the Baseline Findings of Randomized Controlled Trials. Journal of Thoracic Oncology. 5(8). 1233–1239. 45 indexed citations

20.

Abdullah, Shaad E., et al.. (2007). Gross synovial fluid analysis in the differential diagnosis of joint effusion. Journal of Clinical Pathology. 60(10). 1144–1147. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact